Shareholders of Pain Therapeutics, Inc. are reminded of the securities
class action lawsuit filed against PTIE and certain of its officers. The
class action, filed in the United States District Court, Western
District of Texas, is on behalf of a class consisting of all persons or
entities who purchased PTIE securities during the period from February
3, 2011 through June 23, 2011.
If you are a shareholder who purchased PTIE securities during the Class
Period, you have until January 31, 2012 to ask the Court to appoint you
as lead plaintiff for the class. A copy of the complaint can be obtained
at www.pomerantzlaw.com. To discuss this action, contact Rachelle R.
Boyle at rrboyle@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll
free, x350. Those who inquire by e-mail are encouraged to include their
mailing address and telephone number.
The Complaint alleges that, during the Class Period, PTIE made false
and/or misleading statements and/or failed to disclose material facts
about a new drug, REMOXY. Specifically, PTIE failed to disclose that
REMOXY was not approvable by the U.S. Food and Drug Administration due
to chemistry, manufacturing, and control deficiencies that caused
inconsistent results during laboratory tests.
www.pomerantzlaw.com.
No comments:
Post a Comment